CLINICAL_TRIALS
trial_result
· 2011-05-25
Clinical Trial Update: Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease [Phase 3]
Summary
A Phase 3 trial update evaluating long-term safety, efficacy, and corticosteroid-sparing effects of certolizumab pegol in Crohn's disease.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: UCB Pharma | Conditions: Crohn's Disease | Phase 3 | Status: COMPLETED | Results posted: 2011-05-25